Buy CanSino Biologics Inc stock & View ($6185.HK) Share Price on eToro.

Invest

Performance

-11.84% Past Week

Market Cap

10.36B

Day’s Range

41.69

42.69

52W Range

39.99

146.78

Volume (3M)

1.57M

Price-Earnings Ratio

-10.21

Revenue

1.21B

Pinned Post

Edited

@eToroTeam

eToro

12 days ago

📢 Please be informed that due to an issue from our liquidity provider that is currently under investigation the HK stocks were not available for the whole daily session. Thank you, - The eToroTeam

Top Discussions

@MarketUpdates

United Kingdom

3 days ago

$6185.HK (CanSino Biologics Inc) Q1 2023 earnings report is expected to be released

APR

REPORTS

CanSino Biologics Inc Q1 2023 earnings report is expected to be released after market open

6185.HK

CanSino Biologics Inc

41.99

-0.40

(-0.94%)

Trade

@aksus1985

Latvia

5 days ago

My absolutely worst positions are: $888.L (888 Holdings) -64,13% $LUMN (Lumen Technologies Inc) -59,15% $6185.HK (CanSino Biologics Inc) -56,65% $SSSS (SuRo Capital Corp) -53,72% For me is more important to concentrate on making conclusions about what gone wrong and how such investments could be avoided... Show More

@MarketUpdates

United Kingdom

2 months ago

Edited

$6185.HK (CanSino Biologics Inc) Q4 2022 earnings report is expected to be released

MAR

REPORTS

CanSino Biologics Inc Q4 2022 earnings report released after market open

6185.HK

CanSino Biologics Inc

41.99

-0.40

(-0.94%)

Trade

@aksus1985

Latvia

2 months ago

$6185.HK (CanSino Biologics Inc) Looks like it was mistake to invest in this stock. Will hold it, but no further investment in couple next years.

@MarketUpdates

United Kingdom

3 months ago

Edited

$6185.HK (CanSino Biologics Inc) Q4 2022 earnings report is expected to be released

About CanSino Biologics Inc

CanSino Biologics Inc. is a biotechnology and biopharmaceuticals company based in the People’s Republic of China. Originally founded in 2009, CanSino Biologics is primarily focused on the clinical stage vaccine market segment. The company has an international focus in terms of distribution and is currently headquartered in Tianjin in the People’s Republic of China. CanSino Biologics Inc. is listed on the Hong Kong Stock Exchange (HKEX) under the 6185.HK ticker. In terms of the performance of the 6185.HK share price, Cansino Biologics Inc. has posted a 52-week high of 285.20 HKD to a 52-week low of 32.90 HKD. It has been traded on the HKEX since it was first listed in July 2018. CanSino Biologics Inc.’s main commercial interests lie in the development and manufacture of vaccines. Some of its most high-profile vaccines include an Ebola virus vaccine, as well as vaccines for the prevention of N. meningitides. In 2020, CanSino Biologics Inc. signed a collaboration agreement with The National Research Council of Canada and Precision NanoSystems Inc. to develop vaccines to combat COVID-19. It was one of the first companies to secure a patent for its COVID-19 vaccine in China. To keep up to date with the latest news, updates, and financial data on the CanSino Biologics Inc. stock, simply add the 6185.HK ticker to your eToro watchlist.

2.2K

Employees

2009

Founded

Xue Feng Yu, PhD

CEO

Upcoming Earnings

APR

REPORTS

CanSino Biologics Inc Q1 2023 earnings report is expected to be released after market open

ESG: A New Source of Insight

Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.

100

High

Environment

Social

Governance

6185.HK CanSino Biologics Inc

Performance

About CanSino Biologics Inc

Upcoming Earnings

ESG: A New Source of Insight

People Also Bought